23 January 2017 - It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

Kaleo Pharma's Auvi-Q, a competitor to Mylan's EpiPen, will be back on the market in February, the company announced Thursday, but not without a high price tag for insurers and pharmacy benefit managers.

Kaleo's low out-of-pocket price tag on Auvi-Q depends on a complex price structure that forces insurers and pharmacy benefit managers to bear most of the product's costs. While Auvi-Q, an auto-injector used to treat anaphylaxis and severe allergic reactions, will be free for patients with household income of less than $100,000 yearly, a package of two auto-injectors will cost $4,500 for insurance companies and PBMs. For uninsured patients who make over $100,000 yearly, the cost of the auto-injector two pack will be $360.

Read The Street article